08:57:22Philippines

Emergent BioSolutions Inc. (EBS)

NYSE

Key stats Fiscal year 2025

Income statement

Revenue
742,900,000 -28.8%
Net income
52,600,000
Operating income
100,100,000
Earnings per share
0.98
R&D expense
53,200,000

Growth and profitability

Operating margin
13.47
Net margin
7.08
Return on equity
10.07
Return on assets
3.99
Free cash flow margin
21.11

Balance sheet

Total assets
1,318,600,000
Total liabilities
796,000,000
Shareholders' equity
522,600,000
Cash and equivalents
205,400,000
Debt
589,700,000
Net debt
384,300,000
Current ratio
5.01
Debt to equity
1.13

Cash flow and ratios

Operating cash flow
170,600,000
Free cash flow
156,800,000

Shareholder returns

Share buybacks
24,900,000
Shares outstanding
51,415,182
Book value per share
10.16
Revenue and net income
From revenue to profit 2025
Debt, free cash flow and cash
Earnings per share

Company information

Headquarters
Gaithersburg, MD
Exchange
NYSE
Fiscal year end
12-31
Industry (SEC)
Pharmaceutical Preparations

Fiscal year end: · Source: SEC EDGAR

Emergent BioSolutions Inc. trades on NYSE under the ticker symbol EBS. This page brings together its price chart, company profile, key financial figures and technical indicators.

Company profile

Technical analysis